Targeting αvβ8 Integrin with Monoclonal Antibody MEDI8367 Prevents Fibrosis in Preclinical Models of CKD
Our study highlights the potential of MEDI8367 to mitigate renal fibrosis and improve kidney function, offering a novel approach to CKD treatment that complements existing therapies.
Authors
- Shrikant R. Mulay (ORCID: https://orcid.org/0000-0003-4261-445X)
- Jean‐Martin Lapointe (ORCID: https://orcid.org/0000-0003-0141-4603)
- Pernille Hansen (ORCID: https://orcid.org/0000-0003-0661-1665)
- Richard Stebbings (ORCID: https://orcid.org/0000-0001-9628-2708)
- Elena Liarte Marin (ORCID: https://orcid.org/0009-0000-2168-9810)
- James Conway (ORCID: https://orcid.org/0000-0002-1725-8193)
- Sonja Y. Hess (ORCID: https://orcid.org/0000-0002-5904-9816)
- Barbara Hebeis (ORCID: https://orcid.org/0009-0008-8175-1186)
- Kevin Woollard (ORCID: https://orcid.org/0000-0002-9839-5463)
- Lihuan Liang
- Michael C. McCarthy
- Asha Seth (ORCID: https://orcid.org/0000-0003-0813-4620)
- David H. Baker (ORCID: https://orcid.org/0000-0002-8020-3275)
Institutions
- AstraZeneca (South Korea) (KR)
- AstraZeneca (Australia) (AU)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (Germany) (DE)
Publication Details
- Journal
- Kidney360
- Published
- 2025-12-12
- DOI
- https://doi.org/10.34067/kid.0000001006
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00